BBNX
Beta Bionics Inc
NASDAQ · Health Care
$13.08
-0.16 (-1.21%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 66.90M | 236.47M | 231.04M | 255.29M |
| Net Income | -56,245,867 | 30.56M | 29.00M | 38.71M |
| EPS | — | — | — | — |
| Profit Margin | -84.1% | 12.9% | 12.6% | 15.2% |
| Rev Growth | — | +7.0% | -7.5% | +15.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 159.86M | 166.94M | 156.08M |
| Total Equity | — | 327.82M | 355.88M | 355.93M |
| D/E Ratio | — | 0.49 | 0.47 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -59,076,650 | 76.07M | 67.45M | 82.18M |
| Free Cash Flow | — | 21.68M | 20.54M | 23.28M |